BNP-45 rat

BNP-45 rat is a synthetic peptide corresponding to the 45-amino acid form of brain natriuretic peptide (BNP) derived from rat proBNP. As a member of the natriuretic peptide family, it plays a pivotal role in cardiovascular and renal physiology, modulating processes such as natriuresis, diuresis, and vasodilation through cGMP-mediated signaling pathways. The peptide's sequence and structure make it a valuable tool for researchers investigating peptide-receptor interactions, signal transduction mechanisms, and comparative physiology between species. Its biochemical properties enable precise functional studies in both in vitro and in vivo experimental models, supporting a broad range of peptide-centric research applications.

Receptor binding studies: BNP-45 rat is widely utilized to characterize natriuretic peptide receptor subtypes, particularly NPR-A and NPR-B, in rat tissues and heterologous expression systems. By enabling quantitative and qualitative analysis of ligand-receptor interactions, the peptide supports detailed mapping of binding affinities, receptor selectivity, and downstream signaling events. Such studies are essential for elucidating the molecular mechanisms underlying natriuretic peptide-mediated physiological responses and for advancing the understanding of receptor pharmacology in cardiovascular research.

Signal transduction research: As a potent activator of guanylyl cyclase-linked natriuretic peptide receptors, BNP-45 rat is a standard reagent for probing cGMP-dependent signaling cascades. Researchers employ the peptide to stimulate intracellular cGMP production and assess subsequent effects on ion channel activity, protein kinase G activation, and downstream gene expression. These experiments provide critical insights into the regulation of vascular tone, renal function, and cellular homeostasis, facilitating the exploration of peptide-driven signaling networks in health and disease models.

Comparative physiology studies: The species-specific sequence of BNP-45 rat allows for comparative analysis of natriuretic peptide function across different animal models. By using this peptide in parallel with homologous peptides from other species, investigators can delineate evolutionary conservation and divergence in receptor recognition, biological potency, and tissue distribution. Such comparative studies contribute to a more comprehensive understanding of natriuretic peptide biology and inform translational research involving animal models.

Peptide synthesis and analytical validation: BNP-45 rat serves as a reference standard and positive control in peptide synthesis, purification, and analytical method development. Its well-characterized sequence and established bioactivity enable method validation in mass spectrometry, HPLC, and immunoassay platforms. Laboratories rely on the peptide to optimize synthetic protocols, confirm product identity, and calibrate quantitative assays, ensuring the accuracy and reproducibility of peptide-based experimental workflows.

Functional assays in cardiovascular and renal research: The peptide is frequently employed in functional assays designed to assess natriuretic peptide-mediated physiological effects in isolated organ preparations, tissue cultures, and ex vivo systems. By administering BNP-45 rat, researchers can directly evaluate parameters such as vasorelaxation, natriuresis, and diuretic responses under controlled experimental conditions. These applications are central to dissecting the molecular and cellular basis of cardiovascular and renal regulation, supporting the development of new research hypotheses and experimental models.

1. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

4. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment